Erythromycin tablets 250MG
Each tablet contains 250 mg Erythromycin base.
Erythromycin is an antibiotic belonging to the macrolide group and
acts by inhibition of protein synthesis of the micro organisms.
It produces peak plasma levels in one to four hours, depending on
the rapidity of gastric emptying. The level declines after four to
The antibiotic is concentrated in the liver and excreted in active
form in the bile. About 2 - 5% of the drug is excreted in the
urine, also in the active form.
Infections due to susceptible micro-organisms such as gram positive
cocci and bacilli. When possible, cultures and sensitivity tests
should be done.
Erythromycin stearate has been found to be effective in vitro
against Gram-positive organisms such as Staphylococcus aureus*,
Streptococcus pyogenes and Streptococcus viridans *, enterococci
and pneumococci. It also inhibits some strains of Neisseriae,
Haemophilus influenzae, Corynebacterium diphtheriae, Listeria,
Pasteurella and Treponema.
Erythromycin stearate is an alternate treatment for Neisseria
gonorrhoea and primary syphilis (T. pallidum) in patients allergic
to the penicillins. Before treatment of gonorrhoea patients who are
suspected of also having syphilis should have a microscopic
examination for T. pallidum.
Patients with impaired liver function or patients who have
developed jaundice or other symptoms of liver toxicity during
previous treatment with an erythromycin. Known hypersensitivity to
The safety of erythromycin for use during pregnancy and lactation
has not been established.
DOSAGE AND DIRECTIONS FOR USE:
In order to obtain optimal blood levels, Rubimycin should be given
on an empty stomach.
250 to 500 mg every 6 hours depending on the severity of the
The basic recommendation ranges from 30 to 50 mg/kg/day or more,
depending on the severity of the infections: these amounts are
administered in four divided doses.
SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Caution should be taken in administering erythromycin stearate to
patients with impaired hepatic function.
Gastro-intestinal disturbances e.g. nausea, vomiting, abdominal
cramps and diarrhoea may occur. Sensitisation to erythromycin and
hypersensitivity reactions such as fever, eosinophilia and skin
reactions may occur. Anaphylaxis has been reported.
Super-infection caused by resistant organisms.
Pseudo-membranous colitis may occur.
Reversible deafness has occurred after high doses of erythromycin.
Hepatotoxicity has been reported after administration of
erythromycin, but most commonly as the estolate.
Erythromycin should not be given concomitantly with chloramphenicol
or thiamphenicol. Erythromycin may potentiate the action of
carbamazepine, cyclosporin, corticosteroids, digoxin, theophylline
and warfarin, probably by inhibition of their hepatic metabolism.
Keep container tightly closed and store below 25°C. Protect from
KEEP OUT OF REACH OF CHILDREN.